Loading
A phase 2 trial of KC1036 in ewing sarcoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma is a phase 2 interventional study registered as NCT06564272 by Beijing Konruns Pharmaceutical Co., Ltd., with 30 participants planned, started 2024-09-27 and due to reach its primary completion in 2027-04-01. Interventions recorded: KC1036. Conditions listed: Ewing Sarcoma. No results are recorded here; the registry entry is the source.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Beijing Konruns Pharmaceutical, KC1036.